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e would like to applaud the authors of the recent review in JACC
1) regarding the current status of clinical applications of vascular
ndothelial growth factors (VEGFs). As the investigators men-
ioned, VEGF therapy has tremendous potential in vascular
herapeutics, although more clinical data are required to draw safe
onclusions. In their comprehensive review, Ylä-Herttuala et al.
1) focused also on the possible role of VEGF-A in the “destabi-
ization” procedure of atheromatic plaques via proinflammatory
nd angiogenic mechanisms. However, they also cite studies
hallenging the potential detrimental role of VEGF-A on plaque
nstability, as systemic gene transfer of VEGF-A did not alter
laque area, and local gene transfer inhibited neointimal growth in
nimal studies (1).
There is increasing evidence that vasa vasorum-derived micro-
essels nurture the atherosclerotic plaque, with an organized
ystem regulated by sympathetic and hormonal stimuli (2). Re-
ently, we investigated the potential therapeutic effect of local
elivery of an antibody against VEGF-A on neovascularization
nd intimal hyperplasia in an experimental model. Specifically, we
emonstrated that bevacizumab (Avastin, Genentech, South San
rancisco, California), a monoclonal antibody for VEGF-A,
elivered locally by a phosphorylcholine-coated stent is associated
ith less microvessel density and neotintimal hyperplasia com-
ared with the control segments. Moreover, the inflammation,
ndothelialization, and fibrin deposition scores were not affected
y bevacizumab (3). These favorable experimental results were the
timulus to perform the first-in-man study, in which we included
0 patients treated by a bevacizumab-eluting stent (4). Angio-
raphic and intravascular ultrasound examination at 6 months
howed minimal late loss and neointimal hyperplasia area.
Ylä-Herttuala et al. (1) also mentioned that patients under
ystemic administration of bevacizumab for cancer treatment had
n almost 5% increased risk of thromboembolic complications in
ddition to the more common side effects of hypertension androteinuria (5). Thus, local delivery of bevacizumab is required to
vercome the systemic side effects. In this first approach for plaque
eovascularization inhibition we used a coated stent for the local
elivery of bevacizumab. However, new means for local delivery of
ultiple inhibitors of VEGF-A are currently being investigated.
In conclusion, VEGFs may be important therapeutic targets in
ardiovascular therapeutics. Local inhibition of VEGF-A needs to
e further investigated as a new treatment strategy for “high-risk”
laque stabilization.
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